 |
160 Products |  |
813 Diseases | | 160 Products |
|
1554 Trials |  |
75234 News |  |
| «12...7273747576777879808182...858859» |
- | Prolia (denosumab) / Amgen
Retrospective data, Journal: Three-year follow-up of a novel orthopedic ward fracture liaison services (OWFLS) model. (Pubmed Central) - Apr 22, 2024
OWFLS improved the detection rate of bone metabolism indicators, treatment rate, and patient adherence and reduced recurrence of bone pain. OWFLS may be suitable for settings lacking human resources.
- | omecamtiv mecarbil (AMG 423) / Amgen, Servier
Journal: Characterization of NEB pathogenic variants in patients reveals novel nemaline myopathy disease mechanisms and omecamtiv mecarbil force effects. (Pubmed Central) - Apr 22, 2024
Moreover, we propose that the pathomechanism of NEM2 involves not only shortened but also elongated thin filaments, along with the disruption of actin-binding sites resulting from pathogenic splicing variants. Significantly, our findings highlight the potential of OM treatment to improve skeletal muscle function in NEM2 patients, especially those with large reductions in nebulin levels.
- ||| morphine-6-glucuronide (M6G) / PAION
Review, Journal, Adverse events: Incidence of drug-related adverse events related to the use of high-alert drugs: A systematic review of randomized controlled trials. (Pubmed Central) - Apr 22, 2024
The most reported drug classes in the articles included that were related to incidence of drug-related adverse events in use of high-alert medications: morphine, M6G-glucuronide, haloperidol, promethazine, ivabradine, digoxin, warfarin, ximelagatran, cyclophosphamide, cyclosporine, and ATG. The formulate protocols for the use of these medications, with importance placed on evaluating, among the classes, the medication that causes the least harm.
- | Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
New P3 trial: The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study (clinicaltrials.gov) - Apr 22, 2024
P3, N=500, Not yet recruiting, Sponsor: American Society of Clinical Oncology
- ||| AMG 193 / Amgen
Enrollment open: A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (clinicaltrials.gov) - Apr 22, 2024
P1, N=282, Recruiting, Sponsor: Amgen
The formulate protocols for the use of these medications, with importance placed on evaluating, among the classes, the medication that causes the least harm. Not yet recruiting --> Recruiting
- | Lumakras (sotorasib) / Amgen
Journal: ML162 derivatives incorporating a naphthoquinone unit as ferroptosis/apoptosis inducers: Design, synthesis, anti-cancer activity, and drug-resistance reversal evaluation. (Pubmed Central) - Apr 22, 2024
Furthermore, GIC-20 also enhanced the sensitivity of resistant MIA-PaCa-2-AMG510R cells to AMG510, suggesting the great potential of GIC-20 in overcoming the acquired resistance of KRASG12C inhibitors. Overall, GIC-20 represents a novel dual ferroptosis/apoptosis inducer warranting further development for cancer therapeutics and overcoming drug resistance.
- | Prolia (denosumab) / Amgen
Journal, Combination therapy, Checkpoint inhibition, IO biomarker: The RANKL inhibitor denosumab in combination with dual checkpoint inhibition is associated with increased CXCL-13 serum concentrations. (Pubmed Central) - Apr 22, 2024
Denosumab in combination with dual ICI modulates cytokine expression and T-cell composition in peripheral blood. The upregulation of CXCL-13, a key factor for initiating tertiary lymphoid structures, strengthens the hypothesis that denosumab indeed boost immunological effects.
- | Enbrel (etanercept) / Pfizer, Amgen
Journal: Osteoporosis presenting during pregnancy and lactation: wait and reassess. (Pubmed Central) - Apr 22, 2024
Genomic screen was negative but she had mild ankylosing spondylitis previously well controlled on etanercept...The marked increase in bone density resulted from the combined effects of spontaneous recovery and pharmacotherapy. Spontaneous recovery of bone mass and strength should occur during 12
- || Avastin (bevacizumab) / Roche
Retrospective data, Review, Journal, Head-to-Head, Metastases: A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness. (Pubmed Central) - Apr 22, 2024
We evaluated the relative efficacy and safety of first-line EGFRIs plus doublet chemotherapy (FOLFIRI or FOLFOX) vs. bevacizumab plus doublet chemotherapy for patients with RAS WT left-sided mCRC, as well as in all- and right-sided tumors...Safety was available in 6 trials for all-sided tumors and 1 trial for left-sided tumors, each demonstrating typical class-specific adverse events. This most comprehensive meta-analysis indicates a benefit for first-line EGFRI plus chemotherapy over bevacizumab plus chemotherapy in patients with left-sided RAS WT mCRC.
- | Actemra IV (tocilizumab) / Roche, JW Pharma, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
Retrospective data, Journal: Risk factor of non-tuberculous Mycobacterium infection in patients with rheumatoid arthritis and other autoimmune diseases receiving biologic agents: A multicenter retrospective study. (Pubmed Central) - Apr 22, 2024
In the patients undergoing therapy with biologic agents, although NTM complication was rare, it could be fatal. In particular, for patients on a relatively high dose corticosteroids, careful observation is essential for identifying NTM complication, even if the MAC antibody test is negative.
- || Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Clinical, Journal: An investigation of the differential therapeutic effects of romosozumab on postmenopausal osteoporosis patients with or without rheumatoid arthritis complications: a case-control study. (Pubmed Central) - Apr 22, 2024
In particular, for patients on a relatively high dose corticosteroids, careful observation is essential for identifying NTM complication, even if the MAC antibody test is negative. The efficacy of ROMO may be attenuated by RA-related factors.
- | Krystexxa (pegloticase) / Amgen
Enrollment closed: Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome (clinicaltrials.gov) - Apr 22, 2024
P4, N=10, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
The efficacy of ROMO may be attenuated by RA-related factors. Recruiting --> Active, not recruiting
- ||| Stivarga (regorafenib) / Bayer
Trial completion: A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy (clinicaltrials.gov) - Apr 22, 2024
P1, N=62, Completed, Sponsor: Bayer
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
Enrollment open: Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial (clinicaltrials.gov) - Apr 22, 2024
P3, N=408, Recruiting, Sponsor: ECOG-ACRIN Cancer Research Group
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Design of a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of tezepelumab in adult patients with severe chronic rhinosinusitis with nasal polyposis (WAYPOINT) (Poster Zone) - Apr 21, 2024 - Abstract #EAACI2024EAACI_2586;
P3
The safety and tolerability of tezepelumab will also be assessed. Conclusion WAYPOINT aims to evaluate the efficacy and safety of tezepelumab in adult patients with severe CRSwNP.
- briquilimab (JSP191) / Jasper Therap
Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Briquilimab after Single Subcutaneous (SC) Administration to Healthy Male and Female Participants (Poster Zone) - Apr 21, 2024 - Abstract #EAACI2024EAACI_2231;
Conclusion Briquilimab was well tolerated, exhibited a favorable pharmacokinetic profile and a single SC dose was found to result in sustained inhibition of mast cell recruitment in a cutaneous wound model in healthy subjects. PK and PD profiles were used to support dose selection for clinical trials in CSU and CIndU.
- STAR-0310 / Astria Therap
Development and characterization of STAR-0310: a novel OX40 antagonistic monoclonal antibody (Poster Zone) - Apr 21, 2024 - Abstract #EAACI2024EAACI_2143;
Conclusion STAR-0310, an anti-OX40 antibody, demonstrates the potential for increased half-life, high-potency T cell inhibition, and reduced toxicities with minimized effector (ADCC) functions. These promising preclinical findings support the potential use of STAR-0310 in moderate-to-severe AD and other immunologic diseases.
- briquilimab (JSP191) / Jasper Therap
SPOTLIGHT: A Phase 1b/2a, Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients with Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment with H1-Antihis (Poster Zone) - Apr 21, 2024 - Abstract #EAACI2024EAACI_1209;
These promising preclinical findings support the potential use of STAR-0310 in moderate-to-severe AD and other immunologic diseases. Results Safety and tolerability: Review of laboratory data (hematology, clinical chemistry, urinalysis), physical examinations, vital signs, ECG, reports of treatment emergent adverse events (TEAEs) Pharmacokinetics: Cmax, tmax and AUClast Preliminary Efficacy: Change from baseline to Week 12 in provocation testing scores (TempTest
- | Prolia (denosumab) / Amgen
Journal: Bone loss after discontinuation of denosumab: the devil is in the details. (Pubmed Central) - Apr 21, 2024
Bone turnover markers were appropriately suppressed and bone mineral density increased in the spine and hip. This case illustrates how the overshooting phenomenon following denosumab discontinuation may be compounded by the development of secondary conditions, which can result in suboptimal response to antiresorptive osteoporosis medications.
- | Vectibix (panitumumab) / Amgen
Journal, Metastases: Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study. (Pubmed Central) - Apr 20, 2024
The concordance rate between liquid and solid biopsies at baseline was very high, as previously reported, while our results suggest a considerable emergence of RAS mutations during disease progression. Thus, the dynamics of the genomic landscape in ctDNA may provide relevant information for the management of mCRC patients.
- || Ibrance (palbociclib) / Pfizer
Clinical, Observational data, Journal, Real-world evidence, Real-world, Metastases: Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study. (Pubmed Central) - Apr 20, 2024
P=N/A
Thus, the dynamics of the genomic landscape in ctDNA may provide relevant information for the management of mCRC patients. The addition of palbociclib to ET was effective for treating HR+/HER2-?ABC in Japanese routine clinical practice.
- | Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Journal: Reconstruction of Remodeling units reveals positive effects after 2 and 12 (Pubmed Central) - Apr 19, 2024
These evolving bone packets may reflect early stimulation of bone formation that contributes to the increase in completed wall thickness at M12. These data suggest that romosozumab induces a positive bone balance due to its effects on bone resorption and formation at the level of the remodeling unit, contributing to the positive effects on bone mass, structure, and fracture risk.
- | Tepezza (teprotumumab-trbw) / Roche, Amgen
Journal: Teprotumumab improves light sensitivity in patients with thyroid eye disease. (Pubmed Central) - Apr 19, 2024
Teprotumumab improves light sensitivity in patients with acute and chronic TED. The results of this study highlight that the improvements in light sensitivity following treatment are not directly related to the mechanical changes in TED, suggesting another underlying mechanism is
- | Journal: Drug therapy in juvenile spondyloarthritis. (Pubmed Central) - Apr 19, 2024
Long-term follow-up studies continue to demonstrate acceptable safety profiles. There is need for more real-world data on drug efficacy from Registry studies and research on effective de-escalation strategies.
- | Praluent (alirocumab) / Sanofi, Regeneron, Repatha (evolocumab) / Amgen, Astellas
Journal: Safety of Monoclonal Antibodies Inhibiting PCSK9 in Pregnancy: Disproportionality Analysis in VigiBase (Pubmed Central) - Apr 19, 2024
There is need for more real-world data on drug efficacy from Registry studies and research on effective de-escalation strategies. In conclusion, this study showed that, currently, there are no signals of increased reporting of spontaneous abortion with alirocumab and evolocumab compared with the full database and statins in VigiBase
- ||||| rocatinlimab (KHK4083) / Amgen
New P2 trial: A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma (clinicaltrials.gov) - Apr 19, 2024
P2, N=428, Not yet recruiting, Sponsor: Amgen
- || bemarituzumab (AMG 552) / Amgen
Trial primary completion date: FORTITUDE-103: A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. (clinicaltrials.gov) - Apr 19, 2024
P1, N=80, Recruiting, Sponsor: Amgen
In conclusion, this study showed that, currently, there are no signals of increased reporting of spontaneous abortion with alirocumab and evolocumab compared with the full database and statins in VigiBase Trial primary completion date: Nov 2026 --> Mar 2026
- | Stivarga (regorafenib) / Bayer
New P2 trial, Metastases: HCC-HAIC-001: HAIC Combined With PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunotherapy Failure (clinicaltrials.gov) - Apr 19, 2024
P2, N=42, Not yet recruiting, Sponsor: Yehua Shen
- | Ibrance (palbociclib) / Pfizer
Trial completion, Trial completion date, Trial primary completion date, Surgery: NCI-2018-01050: Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer (clinicaltrials.gov) - Apr 18, 2024
P1/2, N=15, Completed, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Nov 2026 --> Mar 2026 Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Apr 2024 | Trial primary completion date: Dec 2025 --> Apr 2024
- ||| Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Journal, Adverse events: CDK4/6 inhibitors in drug-induced liver injury: a pharmacovigilance study of the FAERS database and analysis of the drug-gene interaction network. (Pubmed Central) - Apr 18, 2024
Our study revealed variations in hepatobiliary toxicity among the different CDK4/6 inhibitors, with ribociclib showing the highest risk of liver injury, followed by abemaciclib, while palbociclib appeared relatively safe. Our findings emphasize the need for cautious use of CDK4/6 inhibitors, and regular liver function monitoring is recommended for long-term CDK4/6 inhibitor use.
- || Vectibix (panitumumab) / Amgen
Review, Journal: Comparative aspects of targeted sentinel lymph node mapping in veterinary and human medicine: opportunities for future research. (Pubmed Central) - Apr 18, 2024
In this review, we discuss SLN mapping techniques in veterinary medicine and the concept of precision medicine as it relates to targeted SLN mapping imaging agents. The large number of companion animals affected by cancer is an underutilized resource to bridge the translational gap and we aim to provide a reference for the use of dogs and cats as a comparative model for human SLN mapping.
- || Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
PK/PD data, Journal: Population Pharmacokinetic Modeling and Exposure-Efficacy and Body Weight-Response Analyses for Tezepelumab in Patients With Severe, Uncontrolled Asthma. (Pubmed Central) - Apr 18, 2024
P3
There was no apparent relationship between tezepelumab exposure and efficacy at this dose regimen, suggesting that it is on the plateau of the exposure-response curve of tezepelumab. In conclusion, a fixed-dose regimen of tezepelumab 210 mg subcutaneously Q4W is appropriate for eligible adults and adolescents with severe, uncontrolled asthma.
- | ECT204 / Eureka Therap
Trial completion date, Metastases: ARYA3: T-Cell Therapy (ECT204) in Adults With Advanced HCC (clinicaltrials.gov) - Apr 18, 2024
P2, N=30, Recruiting, Sponsor: Eureka Therapeutics Inc.
In conclusion, a fixed-dose regimen of tezepelumab 210 mg subcutaneously Q4W is appropriate for eligible adults and adolescents with severe, uncontrolled asthma. Trial completion date: Dec 2027 --> Dec 2026
- | Imlygic (talimogene laherparepvec) / Amgen, Yondelis (trabectedin) / PharmaMar, J&J, Opdivo (nivolumab) / BMS
Trial completion date, Trial primary completion date: SOC-1882: Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma (clinicaltrials.gov) - Apr 18, 2024
P2, N=40, Recruiting, Sponsor: Sarcoma Oncology Research Center, LLC
Trial completion date: Dec 2027 --> Dec 2026 Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
- | Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
Enrollment change: Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC (clinicaltrials.gov) - Apr 18, 2024
P2, N=71, Recruiting, Sponsor: University of Wisconsin, Madison
Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Dec 2023 --> Dec 2024 N=110 --> 71
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer, Opdivo (nivolumab) / BMS
Trial completion date, Trial primary completion date: SWOG S1826: Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma (clinicaltrials.gov) - Apr 18, 2024
P3, N=995, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=110 --> 71 Trial completion date: Dec 2032 --> Apr 2025 | Trial primary completion date: Jun 2023 --> Mar 2024
- ||| sovilnesib (AMG 650) / Volastra Therap
Enrollment open, Phase classification, Metastases: A Study of Sovilnesib in Subjects with Ovarian Cancer (clinicaltrials.gov) - Apr 18, 2024
P1, N=120, Recruiting, Sponsor: Volastra Therapeutics, Inc.
Trial completion date: Dec 2032 --> Apr 2025 | Trial primary completion date: Jun 2023 --> Mar 2024 Not yet recruiting --> Recruiting | Phase classification: P1b --> P1
- ||| BMS-986288 / BMS, Opdivo (nivolumab) / BMS
Enrollment closed: An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers (clinicaltrials.gov) - Apr 17, 2024
P1/2, N=494, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting | Phase classification: P1b --> P1 Recruiting --> Active, not recruiting
- |||| zunsemetinib (ATI-450) / Aclaris
New P1/2 trial: Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis (clinicaltrials.gov) - Apr 17, 2024
P1/2, N=138, Not yet recruiting, Sponsor: Washington University School of Medicine
- | Ibrance (palbociclib) / Pfizer, Herceptin (trastuzumab) / Roche
Trial completion: PATRICIA: Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer (clinicaltrials.gov) - Apr 17, 2024
P2, N=73, Completed, Sponsor: SOLTI Breast Cancer Research Group
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || STX-478 / Scorpion Therap
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: STX-478-101: First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Apr 17, 2024
P1/2, N=400, Recruiting, Sponsor: Scorpion Therapeutics, Inc.
Active, not recruiting --> Completed Trial completion date: Apr 2028 --> Feb 2029 | Trial primary completion date: Apr 2026 --> Feb 2027
- | Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Repatha (evolocumab) / Amgen, Astellas
Retrospective data, Journal: Effect of Empagliflozin with or without the Addition of Evolocumab on HDL Subspecies in Individuals with Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EXCEED-BHS3 Trial. (Pubmed Central) - Apr 17, 2024
Over a 16-week period, empagliflozin with or without the addition of evolocumab led to a modest but significant increase in HDL-C. The rise in smaller-sized HDL particles was heterogeneous amongst the treatment combinations.
- || Review, Journal: CC Chemokine Family Members' Modulation as a Novel Approach for Treating Central Nervous System and Peripheral Nervous System Injury-A Review of Clinical and Experimental Findings. (Pubmed Central) - Apr 17, 2024
This review will display the evidence that a multidirectional strategy based on the modulation of neuronal-glial-immune interactions can significantly improve the health of patients after CNS and PNS damage by changing the activity of chemokines belonging to the CC family. Moreover, in the case of pain, the combined administration of such antagonists with opioid drugs could reduce therapeutic doses and minimize the risk of complications.
- | Krystexxa (pegloticase) / Amgen
Biomarker, Retrospective data, Journal: Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation. (Pubmed Central) - Apr 17, 2024
Based on this analysis, only half of those starting another ULT achieved target SU. Close follow-up is needed to optimize outcomes after pegloticase discontinuation.
- | Journal: Monoclonal antibody therapies for aquaporin-4-immunoglobulin G-positive neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease. (Pubmed Central) - Apr 17, 2024
Most recently, ravulizumab (anti-C5 complement inhibitor) was also shown to be highly efficacious in an open-label, external-controlled trial...Observational studies showed that tocilizumab was associated with a decrease in relapses, whereas rituximab seemed to have less robust effectiveness in MOGAD compared to AQP4-IgG+NMOSD. Herein, we review the evidence on the efficacy and safety of each monoclonal antibody therapy used in AQP4-IgG+NMOSD and MOGAD, including special considerations in children and women of childbearing potential.
- | Tepezza (teprotumumab-trbw) / Roche, Amgen
Journal: Teprotumumab in thyroid eye disease. (Pubmed Central) - Apr 17, 2024
In this review, we summarize the clinical features and pathophysiology of TED, disease course, and traditional management methods. We further detail the development of teprotumumab, the founding studies that brought it to its FDA approval, adverse events profile, and ongoing as well as future investigations.
- || efruxifermin (AKR-001) / Akero Therap
Biomarker, Retrospective data, Review, Journal, MRI: Efficacy of pharmacologic interventions on magnetic resonance imaging biomarkers in patients with nonalcoholic fatty liver disease: systematic review and network meta-analysis. (Pubmed Central) - Apr 17, 2024
We further detail the development of teprotumumab, the founding studies that brought it to its FDA approval, adverse events profile, and ongoing as well as future investigations. Several drug classes may reduce LFC in patients with NAFLD without a significant effect on fibrosis; nevertheless, trial duration was small, and confidence in the effect estimates was low.
- | Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Preclinical, Journal: Influence of anti-sclerostin monoclonal antibody in the repair of post-extraction sockets of ovariectomized rats. (Pubmed Central) - Apr 17, 2024
Several drug classes may reduce LFC in patients with NAFLD without a significant effect on fibrosis; nevertheless, trial duration was small, and confidence in the effect estimates was low. Scl-Ab-based medication did not accelerate alveolar bone formation but exhibited better post-extraction repair characteristics, and collagen content compared to ovariectomized animals only.
- | Trial completion date: Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma (clinicaltrials.gov) - Apr 17, 2024
P2, N=71, Active, not recruiting, Sponsor: The Hospital for Sick Children
Scl-Ab-based medication did not accelerate alveolar bone formation but exhibited better post-extraction repair characteristics, and collagen content compared to ovariectomized animals only. Trial completion date: Dec 2023 --> Dec 2024
- ||| Bmab 1000 (denosumab biosimilar) / Biocon, Yoshindo
Trial completion, Trial completion date, Trial primary completion date: Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Bmab 1000 and Prolia (clinicaltrials.gov) - Apr 17, 2024
P1, N=190, Completed, Sponsor: Biocon Biologics UK Ltd
Trial completion date: Dec 2023 --> Dec 2024 Active, not recruiting --> Completed | Trial completion date: Feb 2024 --> Oct 2023 | Trial primary completion date: Feb 2024 --> Oct 2023